GLUE Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutical…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a […] | ||
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve | ||
 Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal Monte Rosa Therapeutics, Inc. recently reported second-quarter 2026 results showing a net loss of US$43.4 million, up from US$12.3 million a year earlier, with basic and diluted loss per share widening to US$0.43 from US$0.15. For the first half of 2026, the company swung from net income of US$34.59 million to a net loss of US$87.9 million, marking a sharp reversal in its earnings profile. Next, we’ll examine how this sharp widening of losses shapes Monte Rosa Therapeutics’ investment... | ||
 Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever. | ||
 Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial Novo Nordisk (NVO) shares tumbled Friday after the Danish pharmaceutical giant said a late-stage tri | ||